Referências

1. Arvanitaki A, Michou E, Kalogeropoulos A, Karvounis H, Giannakoulas G. Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations.ESC Heart Failure. 2020 Aug;7(4):1477-1487. https://doi:10.1002/ehf2.12701. 2. Niklasson A, Maher J, Patil R, Sillén H, Chen J, Gwaltney C, et al. Living with heart failure: patient experiences and implications for physical activity and daily living. ESC Heart Fail. 2022 Apr;9(2):1206-1215. https://doi:10.1002/ehf2.13795. 3. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart Assoc. 2019;8(13):e012272. https://doi:10.1161/JAHA.119.012272 4. Polito MV, Silverio A, Rispoli A, Vitulano G, Auria F, De Angelis E, et al. Clinical and echocardiographic benefit of Sacubitril/Valsartan in a real-world population with HF with reduced ejection fraction. Sci Rep. 2020;10(1):6665. Published 2020 Apr 20. https:// doi:10.1038/s41598-020-63801-2 5. Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, et al. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril- Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction JAMA. 2019 Sep 17;322(11):1085-1095. https://doi:10.1001/ jama.2019.12821. 6. Panagopoulou V, Deftereos S, Kossyvakis C, Raisakis K, Giannopoulos G, Bouras G, et al. NTproBNP: an important biomarker in cardiac diseases. Curr Top Med Chem. 2013;13(2):82- 94. https://doi:10.2174/156802661131302000 7. Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, et al. Effects of Sacubitril/ Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol. 2018 Jun 1;3(6):498-505. https://doi:10.1001/jamacardio.2018.0398. 8. Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL, et al. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circ Heart Fail. 2017 Aug;10(8):e003430.